Petosemtamab
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Petosemtamab, covering 2026-03-31 to 2026-04-22. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) [Phase 3]